Equilibrium contrast CMR for the measurement of diffuse myocardial fibrosis
- PDF / 884,955 Bytes
- 2 Pages / 610 x 792 pts Page_size
- 4 Downloads / 202 Views
BioMed Central
Open Access
Oral presentation
Equilibrium contrast CMR for the measurement of diffuse myocardial fibrosis Andrew S Flett*1, Martin Harward1, Michael T Ashworth2, Michael S Hansen2, Andrew M Taylor2, Shyam Kolvekar1, John Yap1, Perry Elliott1, Christopher McGregor1 and James C Moon1 Address: 1The Heart Hospital, London, UK and 2Great Ormond Street Hospital, London, UK * Corresponding author
from 13th Annual SCMR Scientific Sessions Phoenix, AZ, USA. 21-24 January 2010 Published: 21 January 2010 Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):O16
doi:10.1186/1532-429X-12-S1-O16
Abstracts of the 13th Annual SCMR Scientific Sessions - 2010
Meeting abstracts - A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/files/pdf/1532-429X-11-S1-infoThis abstract is available from: http://jcmr-online.com/content/12/S1/O16 © 2010 Flett et al; licensee BioMed Central Ltd.
Introduction Diffuse myocardial fibrosis (DMF) is a final endpoint in most cardiac diseases. It is missed by the late gadolinium enhancement technique. Currently, the only method to quantify DMF is biopsy, which has risk and is prone to sampling error.
Purpose We have developed a new technique Equilibrium Contrast CMR (EQ-CMR) - the first clinically applicable, robust, noninvasive method to quantify DMF and show it to be accurate against the current gold-standard of surgical myocardial biopsy.
Methods The three elements of EQ-CMR are: a bolus of extra-cellular Gd-DTPA contrast followed by continuous infusion to
achieve equilibrium; a blood sample to measure blood volume of distribution, Vd(b) (one minus haematocrit); and CMR to measure pre and post equilibrium T1 (with heart rate correction). Vd(m) is calculated, reflecting DMF. Equilibrium acquisition was optimized in 16 individuals and achieved by a combination of loading bolus and slow continuous infusion. The T1 measurement technique and heart rate correction was validated in phantoms against T1 relaxometry and then against blood [Gd-DTPA]. Clinical validation was in patients undergoing AVR for AS or myectomy in HCM (n = 18 and 8 respectively). The surgical biopsies were analyzed using fully automated image analysis (macros in ImageJ) for picro-sirius red fibrosis quantification on histology. The scan protocol is outlined in Figure 1.
Figure 1
Page 1 of 2 (page number not for citation purposes)
Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):O16
http://jcmr-online.com/content/12/S1/O16
Figure 2
Results Equilibrium was achieved in all patients within 40 minutes. The second scan took 5 mins ± 42 secs (9 breathholds). The mean histological fibrosis was 20.5% ± 11% in AS and 17.1% ± 7.4 in HCM (Figure 2). The total GdDTPA dose was 0.14 ± 0.001 mmol/kg. EQ-CMR Vd(m) correlated strongly with biopsy histological fibrosis: AS: r2 = 0.86, p < 0.001; HCM: r2 = 0.62, p < 0.02; combined r2 = 0.80, p < 0.001 (Figure 3).
Conclusion We have developed and validated a new technique, EQCMR to m
Data Loading...
